New approaches to improve risk stratification in prostate cancer

Poster Session 29

Saturday 17 March
16:00 - 17:30

Location: Blue Area, Room 2 (Level 0)

Chairs: F. Abdollah, West Bloomfield (US)
G. Gandaglia, Milan (IT)
C. Thomas, Mainz (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 380

**Comprehensive molecular profiling of multifocal prostate cancer challenges the robustness of prostate cancer prognostic signatures**

By: Salami S. ¹, Hovelson D. ², Kaplan J. ², Mathieu R. ³, Udager A. ², Curci N. ⁴, Lee M. ¹, Lazo De La Vega L. ², Susani M. ⁵, Rioux-Leclercq N. ⁶, Spratt D. ⁷, Morgan T. ¹, Davenport M. ⁴, Rubin M. ⁸, Shariat S. ³, Tomlins S. ², Palapattu G. ¹

¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America,
²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America,
³Medical University Vienna, Dept. of Urology, Vienna, Austria,
⁴University of Michigan, Dept. of Radiology, Ann Arbor, United States of America,
⁵Medical University Vienna, Dept. of Pathology, Vienna, Austria,
⁶Rennes University Hospital, Dept. of Pathology, Rennes, France,
⁷University of Michigan, Dept. of Oncology, Ann Arbor, United States of America,
⁸Weill Cornell Medicine, Dept. of Pathology, New York, United States of America

381

**A multi-centre evaluation of the role of Prostate Health Index (PHI) in regions with different prevalences of prostate cancer: A different reference range is needed for European and Asian**

By: Chiu P.K. ¹, Ng C.F. ², Semjonow A. ³, Vincendeau S. ⁴, Houlgatte A. ⁵, Lazzeri M. ⁶, Guazzoni G. ⁷, Stephan C. ⁸, Haese A. ⁹, Bruijne I. ¹, Teoh J.Y. ¹⁰, Chiang C.H. ¹¹, Tan L.G. ¹², Chiong E. ¹², Huang C.Y. ¹³, Wu H.C. ¹⁴, Ye D. ¹⁵, Zhu Y. ¹⁵, Bangma C.H. ¹, Roobol M.J. ¹

¹Erasmus MC, Dept. of Urology, Rotterdam, Netherlands,
²SH Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong,
³Prostate Center, University Clinic Münster, Dept. of Urology, Münster, Germany,
⁴Hospital Pontchaillou, Dept. of Urology, Rennes, France,
⁵HIA Du Val De Grace, Dept. of Urology, Paris, France,
⁶Istituto Clinico -Clinical and Research Hospital Humanitas, Dept. of Urology, Rozzano, Italy,
⁷San Raffaele Hospital-Turro, Dept. of Urology, Milan, Italy,
⁸Charité-Universitätsmedizin and Berlin Institute for Urologic Research, Dept. of Urology, Berlin, Germany,
⁹Martini Clinic Prostate Cancer Centre, University Clinic Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany,
¹⁰Prince of Wales Hospital, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong,
¹¹Taipei
Veterans General Hospital and Su-Ao/Yuan-Shan Branch, Dept. of Surgery, Yi-Lan, Taiwan, University Surgical Cluster, National University Health System, Dept. of Urology, Singapore, Singapore, National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, China Medical University, Dept. of Urology, Taichung, Taiwan, Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

382 Withdrawn
To be confirmed

383 Neutrophil to lymphocyte ratio is associated with lymph node invasion and higher nodal burden in contemporary high risk patients treated with radical prostatectomy and extended pelvic lymph node dissection

By: Bravi C.A.1, Bianchi M.1, Fossati N.1, Gandaglia G.1, Zaffuto E.1, Scuderi S.1, Robesti D.1, Barletta F.1, Nocera L.1, Capitanio U.1, Gallina A.1, Suardi N.2, Shariat S.3, Karakiewicz P.I.4, Montorsi F.1, Briganti A.1
1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2San Raffaele Hospital Turro, Dept. of Urology, Milan, Italy, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria, 4Cancer Prognostics and Health Outcomes Unit, Dept. of Urology, Montreal, Canada

384 Thrombospondin 1 and cathepsin D improve the detection of high-grade prostate cancer and reduce the number of unnecessary prostate biopsies

By: Klocker H.1, Steiner E.1, Horninger W.1, Thomas S.2, Tennstedt P.2, Macagno A.3, Athanasiou A.3, Wittig A.3, Huber R.3, Schiess R.3, Gillessen S.4
1Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, 2University-Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3ProteoMediX, Dept. of Urology, Schlieren, Switzerland, 4St. Gallen and University of Bern, Dept. of Urology, St. Gallen, Switzerland

385 Defining a favorable intermediate-risk group: Utility of magnetic resonance imaging and genetic tests

Mount Sinai Hospital, Dept. of Urology, New York, United States of America

386 Association between prostate cancer and metabolic health status: Korean National Health Check-up data

By: Kim J.W.1, Jeong H.G.1, Park T.Y.1, Ahn S.T.1, Oh M.M.1, Moon D.G.1, Cheon J.2, Lee J.G.2, Park H.S.1
1Korea University Guro Hospital, Dept. of Urology, Seoul, Korea, South, 2Korea University College of Medicine, Dept. of Urology, Seoul, Korea, South

387 Major adverse cardiac events (MACE) are not associated with prostate cancer diagnosis or grade: An Italian biopsy cohort study
388 Prediction of significant prostate cancer in patients with previously negative prostate biopsy undergoing MRI/ultrasound-fusion biopsy in combination with systematic biopsy

By: Borkowetz A., Renner T., Schlumberger G., Platzek I., Toma M., Froehner M., Zastrow S., Wirth M.

1Technische Universität Dresden, Dept. of Urology, Dresden, Germany, 2Technische Universität Dresden, Dept. of Radiology, Dresden, Germany, 3University of Bonn, Dept. of Pathology, Bonn, Germany

389 Urinary steroidal profile as innovative and not expensive tool in differential diagnosis between benign prostate hyperplasia and prostate carcinoma


1San Luigi Gonzaga Hospital, Dept. of Urology, Orbassano, Italy, 2San Luigi Gonzaga Hospital, Antidoping Center, Orbassano, Italy

390 Comparison with diagnostic performance between aberrant glycosylated S2,3PSA test and conventional PSA tests


1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Wako Pure Chemical Industries, Diagnostics Research Laboratories, Hyogo, Japan, 3Akita University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 4Tohoku University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 5McMaster University, Dept. of Surgery, Hamilton, Canada

391 Distinct immunohistochemical findings for common biomarkers in malignant and adjacent benign prostate: A study on needle biopsy microarrays derived from mpMRI-characterized tissue


1University College London, Division of Surgery and Interventional Science, London, United Kingdom, 2Hospital Huriez, University Lille Nord de France, Dept. of Urology, Lille, France, 3University College London Hospital NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, 4University College London Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 5The Royal Free NHS Foundation Trust, Dept.
392  Tumour-associated macrophages in prostate biopsy determined by automated image analysis are an independent prognostic marker for biochemical recurrence in prostate cancer patients

By: Buchner A., Athelogou M., Hessel H., Huss R., Kirchner T., Stief C.

Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, Definiens AG, Dept. of Research, Munich, Germany, Ludwig-Maximilians-University Munich, Dept. of Pathology, Munich, Germany

393  What patient factors predict PSA testing among men aged 50 and above

By: Goldberg H., Klaassen Z., Chandrasekar T., Wallis C., Kulkarni G., Hamilton R., Finelli A., Fleshner N.

Princess Margaret Hospital, Dept. of Urology, Toronto, Canada